Section
This systematic review and meta-analysis evaluates 15 HS-specific PROMs using the COSMIN framework, identifying 7 recommended instruments and highlighting the superior psychometric performance of HiSQOL-17 while uncovering significant gaps
Researchers have developed and validated the TIP-CA model, a clinical tool using five key factors—anti-TIF1-γ, ILD absence, poikiloderma, DM subtype, and anemia—to accurately predict malignancy risk in patients with dermatomyositis, enablin
This review synthesizes findings from the CLEAN-IT trial and historical data to evaluate the impact of chlorhexidine bathing on nosocomial infections, MDR pathogens, and reserve antibiotic consumption in critically ill patients.
The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab
Researchers have developed the first Patient Decision Aid (PDA) specifically for adult systemic atopic dermatitis treatments. The study highlights a ‘staged approach’ that balances clinician-driven data requirements with patient
The Phase 3 LIBERTY-CSU CUPID trials demonstrate that dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria uncontrolled by antihistamines, providing a crucial new therapeutic option for those who are
The BE RADIANT trial demonstrates that bimekizumab provides rapid, superior, and durable skin clearance (PASI 100) and symptom relief compared to secukinumab over three years, with a manageable safety profile and significant quality-of-life
The RESMAIN trial demonstrates that resminostat maintenance therapy doubles median progression-free survival in patients with advanced mycosis fungoides or Sézary syndrome, offering a potential new standard for managing patients who have ac
A systematic review of 1,802 patients reveals that COL7A1 variant type and location, particularly premature termination codons and NC1 domain involvement, are definitive predictors of clinical severity and systemic complications in recessiv
A large-scale study within the VA health system identifies Agent Orange exposure as a significant risk factor for acral melanoma, while highlighting distinct clinical profiles and a paradoxical inverse association with smoking compared to o
The final 9-year analysis of the CheckMate 238 trial confirms that adjuvant nivolumab provides a sustained recurrence-free survival advantage over ipilimumab in patients with resected high-risk melanoma, with 44% of patients remaining recur
Researchers have developed a novel P/G@IYCe dressing combining yolk immunoglobulins and cerium oxide nanoparticles. This synergy effectively neutralizes bacterial pathogens and reactive oxygen species, facilitating rapid, high-quality skin
This review synthesizes findings from a Phase 2 trial of ICP-332, a novel TYK2 inhibitor, demonstrating significant EASI score improvements and a manageable safety profile in moderate to severe atopic dermatitis.
This study identifies activating EGFR L858R variants as the genetic basis for a syndrome featuring generalized acanthosis nigricans and lung nodules, highlighting the efficacy of EGFR inhibitors in treating both cutaneous and systemic manif
A multicenter study reveals significant discordance between clinician and patient assessments of skin cGVHD. While both correlate with survival, patient-reported outcomes are uniquely predictive of mortality in sclerotic disease, highlighti
A large-scale multicentre clinical trial reveals that 5% permethrin cream is significantly more effective than oral ivermectin for treating scabies in households, providing crucial evidence for public health and clinical practice.
A Phase II trial demonstrates that combining lenvatinib with pembrolizumab prior to surgery in Merkel cell carcinoma results in a 57.7% pathological complete response rate, suggesting a highly effective new strategy for managing resectable
The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, high
The Phase 3 VIITAL trial demonstrates that prademagene zamikeracel, an autologous gene-modified cellular sheet, significantly improves healing and reduces pain in patients with recessive dystrophic epidermolysis bullosa (RDEB), offering a t
A Phase IIB trial demonstrates that denovoSkin™, an autologous bio-engineered skin graft, offers a significantly higher expansion ratio and superior scar outcomes compared to split-thickness skin grafts in burn patients, potentially revolut
